Biotech Values

[DewDiligence]

FDA advisory_panel_endorses CDTX’s Rezafungin by 14-1 vote—(stock currently halted):

$CDTX Cidara Therapeutics Adcom Question:
Is the overall benefit-risk assessment favorable for the use of rezafungin for treatment of candidiasis/invasive candidiasis in adults with limited or no alternative treatment options?

Yes: 14
No: 1
POSITIVE ADCOM RECOMMENDATION pic.twitter.com/SK2hjcY9FQ

— TwongStocks (@TwongStocks) January 24, 2023